According to the 2026 American Heart Association/American Stroke Association (AHA/ASA) Guideline for the Early Management of Patients With Acute Ischemic Stroke, the efficacy of intravenous (IV) tirofiban to improve clinical outcomes in patients with acute ischemic stroke (AIS) is not well established. Although early indications suggest that IV tirofiban may enhance recanalization rates when used with intravenous thrombolysis (IVT), definitive data on long-term safety and functional benefits remain limited. Additional research is needed to determine optimal patient selection, such as those with large-vessel occlusion (LVO) or who are undergoing bridging therapies, to establish dosing regimens, and to clarify the interplay of tirofiban’s platelet inhibition with thrombolytics to mitigate hemorrhagic risk. Ongoing large multicenter trials aim to validate these preliminary safety findings, define net clinical benefit, and refine treatment protocols. In contrast, for patients with noncardioembolic AIS or transient ischemic attack (TIA), antiplatelet therapy is indicated in preference to oral anticoagulation to reduce the risk of recurrent ischemic stroke and other cardiovascular events while minimizing the risk of bleeding. The selection of an antiplatelet agent for early secondary stroke prevention should be individualized based on patient risk factor profiles, cost, tolerance, relative known efficacy of the agents, and other clinical considerations. The use of tirofiban in this context is not detailed or recommended for noncardioembolic stroke. [1]
Given the uncertainty in current guidelines about the efficacy of IV tirofiban for AIS, investigators have assessed its use in combination with reperfusion therapy versus reperfusion therapy alone. A 2025 meta-analysis evaluated seven randomized controlled trials comprising 1,607 patients, of whom 815 received tirofiban with reperfusion therapy and 792 received reperfusion therapy alone. The addition of tirofiban was associated with a higher rate of favorable functional outcomes (risk ratio [RR] 1.25, 95% confidence interval [CI] 1.11 to 1.40; p<0.001) and less functional disability (RR 0.72, 95% CI 0.53 to 0.98; p<0.05). Tirofiban also significantly improved National Institutes of Health Stroke Scale (NIHSS) scores at seven days (mean difference [MD] -2.27, 95% CI -4.32 to -0.22; p= 0.03). Rates of successful revascularization were similar between the tirofiban and control groups (RR 1.18, 95% CI 0.97 to 1.45; p= 0.09). Tirofiban did not significantly increase the risk of symptomatic intracranial hemorrhage (sICH; RR 1.47, 95% CI 0.98 to 2.19; p= 0.06), but there was a higher risk of any intracranial hemorrhage (ICH), particularly in patients undergoing endovascular thrombectomy (EVT; RR 1.25, 95% CI 1.03 to 1.51; p= 0.02). Mortality rates were similar between groups (RR 1.05, 95% CI 0.80 to 1.38; p= 0.72). Overall, the addition of tirofiban to reperfusion therapy improved functional outcomes and NIHSS scores without significantly increasing sICH or mortality, although the risk of any ICH was higher in EVT patients. Importantly, the analysis did not report stroke etiology or stratify results by subtype, so the patient population was likely mixed with respect to cardioembolic and non-cardioembolic strokes; the findings may lack generalizability to non-cardioembolic stroke patients specifically. [2]
Another meta-analysis evaluated the safety and efficacy of tirofiban in patients with AIS. The analysis included 17 studies comprising 2,914 patients and compared outcomes between patients treated with tirofiban and those who did not receive tirofiban. Pooled results showed that tirofiban did not increase the risk of symptomatic intracranial hemorrhage (sICH; odds ratio [OR] 0.95, 95% CI 0.71 to 1.28; p= 0.75) or mortality (OR 0.80; 95% CI 0.64 to 1.02; p= 0.07). However, fatal ICH occurred more frequently in the tirofiban group (OR 2.84; 95% CI 1.38 to 5.85; p= 0.005). Subgroup analysis suggested that intra-arterial administration was associated with an increased risk of fatal ICH (OR 2.90; 95% CI 1.12 to 7.55; p= 0.03), whereas intravenous administration was not (OR 2.75; 95% CI 0.92 to 8.20; p= 0.07). Tirofiban was not associated with a significant improvement in functional outcomes, defined as modified Rankin Scale (mRS) 0 to 2 at three months (OR 1.29; 95% CI 0.97 to 1.71; p= 0.08). Unfortunately, subgroup analyses were performed based on route of administration rather than stroke etiology, limiting the ability to determine whether these findings apply specifically to noncardioembolic stroke. [3]
A 2025 prospective, nonrandomized comparative study evaluated the effectiveness and safety of intra-arterial tirofiban in patients with acute ischemic stroke without large- or medium-vessel occlusion. Sixty patients presenting within 24 hours of symptom onset were allocated by patient preference to receive either intra-arterial tirofiban via catheterization followed by dual antiplatelet therapy or intravenous tirofiban with the same antiplatelet regimen. Both groups experienced significant reductions in National Institutes of Health Stroke Scale scores after treatment; however, the intra-arterial group demonstrated significantly lower scores at 24 hours, 72 hours, and 14 days, as well as improved functional outcomes at 90 days, including lower modified Rankin Scale scores and higher Barthel Index scores. The incidence of adverse events did not differ significantly between groups. Interpretation of these findings is limited because the study used a nonrandomized patient-preference allocation design and is currently available only in abstract form, limiting full evaluation of the methodology and results. [4]
The Clinical Trials database lists the ongoing CHANCE-4 Trial (Tirofiban for Patients With Intracranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events), a multicenter, double-blind, double-dummy, randomized clinical trial that will evaluate the efficacy and safety of tirofiban compared with placebo for the prevention of recurrent stroke in patients with intracranial artery stenosis and high-risk acute non-disabling cerebrovascular events. Participants will be randomized 1:1 to receive tirofiban or placebo within 24 hours of symptom onset. The tirofiban group will receive an initial infusion of 0.4 mcg/kg/min for 30 minutes (maximum 1 mg), followed by a continuous infusion of 0.1 mcg/kg/min for 48 hours. The primary efficacy outcome will be any new ischemic stroke at 3 months, and the primary safety outcome will be type 3 or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) criteria at 3 months. The trial is currently recruiting with an estimated trial completion date of December 2026; no results have been reported. [5]